<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36241230</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1671-167X</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences</Title><ISOAbbreviation>Beijing Da Xue Xue Bao Yi Xue Ban</ISOAbbreviation></Journal><ArticleTitle>[Genetic distribution in Chinese patients with hereditary peripheral neuropathy].</ArticleTitle><Pagination><StartPage>874</StartPage><EndPage>883</EndPage><MedlinePgn>874-883</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To analyze the distribution characteristics of hereditary peripheral neuropathy (HPN) pathogenic genes in Chinese Han population, and to explore the potential pathogenesis and treatment prospects of HPN and related diseases.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Six hundred and fifty-six index patients with HPN were enrolled in Peking University Third Hospital and China-Japan Friendship Hospital from January 2007 to May 2022. The <i>PMP22</i> duplication and deletion mutations were screened and validated by multiplex ligation probe amplification technique. The next-generation sequencing gene panel or whole exome sequencing was used, and the suspected genes were validated by Sanger sequencing.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Charcot-Marie-Tooth (CMT) accounted for 74.3% (495/666) of the patients with HPN, of whom 69.1% (342/495) were genetically confirmed. The most common genes of CMT were <i>PMP22</i> duplication, <i>MFN2</i> and <i>GJB1</i> mutations, which accounted for 71.3% (244/342) of the patients with genetically confirmed CMT. Hereditary motor neuropathy (HMN) accounted for 16.1% (107/666) of HPN, and 43% (46/107) of HPN was genetically confirmed. The most common genes of HMN were HSPB1, aminoacyl tRNA synthetases and <i>SORD</i> mutations, which accounted for 56.5% (26/46) of the patients with genetically confirmed HMN. Most genes associated with HMN could cause different phenotypes. HMN and CMT shared many genes (<i>e.g. HSPB1</i>, <i>GARS</i>, <i>IGHMBP2</i>). Some genes associated with dHMN-plus shared genes associated with amyotrophic lateral sclerosis (<i>KIF5A</i>, <i>FIG4</i>, <i>DCTN1</i>, <i>SETX</i>, <i>VRK1</i>), hereditary spastic paraplegia (<i>KIF5A</i>, <i>ZFYVE26</i>, <i>BSCL2</i>) and spinal muscular atrophy (<i>MORC2</i>, <i>IGHMBP</i>, <i>DNAJB2</i>), suggesting that HMN was a continuum rather than a distinct entity. Hereditary sensor and autosomal neuropathy (HSAN) accounted for a small proportion of 2.6% (17/666) in HPN. The most common pathogenic gene was <i>SPTLC1</i> mutation. <i>TTR</i> was the main gene causing hereditary amyloid peripheral neuropathy. The most common types of gene mutations were p.A117S and p.V50M. The symptoms were characterized by late-onset and prominent autonomic nerve involvement.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">CMT and HMN are the most common diseases of HPN. There is a large overlap between HMN and motor-CMT2 pathogenic genes, and some HMN pathogenic genes overlap with amyotrophic lateral sclerosis, hereditary spastic hemiplegia and spinal muscular atrophy, suggesting that there may be a potential common pathogenic pathway between different diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>X X</ForeName><Initials>XX</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>X H</ForeName><Initials>XH</Initials><AffiliationInfo><Affiliation>Department of Neurology, China-Japan Friendship Hospital, Beijing 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>A P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Y S</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>D S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing 100191, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Beijing Da Xue Xue Bao Yi Xue Ban</MedlineTA><NlmUniqueID>101125284</NlmUniqueID><ISSNLinking>1671-167X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C121958">DNAJB2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005420">Flavoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050956">HSP40 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C489892">IGHMBP2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C500506">KIF5A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C549896">MORC2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064251">Multifunctional Enzymes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>9014-25-9</RegistryNumber><NameOfSubstance UI="D012343">RNA, Transfer</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C109890">VRK1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.-</RegistryNumber><NameOfSubstance UI="C522215">FIG4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.2</RegistryNumber><NameOfSubstance UI="D010744">Phosphoric Monoester Hydrolases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C484368">SETX protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.-</RegistryNumber><NameOfSubstance UI="D004265">DNA Helicases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber><NameOfSubstance UI="D020365">RNA Helicases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.4</RegistryNumber><NameOfSubstance UI="D016547">Kinesins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 6.-</RegistryNumber><NameOfSubstance UI="D008025">Ligases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002607" MajorTopicYN="Y">Charcot-Marie-Tooth Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004265" MajorTopicYN="N">DNA Helicases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005420" MajorTopicYN="N">Flavoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050956" MajorTopicYN="N">HSP40 Heat-Shock Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016547" MajorTopicYN="N">Kinesins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008025" MajorTopicYN="N">Ligases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064251" MajorTopicYN="N">Multifunctional Enzymes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009134" MajorTopicYN="Y">Muscular Atrophy, Spinal</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010744" MajorTopicYN="N">Phosphoric Monoester Hydrolases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020365" MajorTopicYN="N">RNA Helicases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012343" MajorTopicYN="N">RNA, Transfer</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="chi"><AbstractText Label="&#x76ee;&#x7684;">&#x5206;&#x6790;&#x4e2d;&#x56fd;&#x6c49;&#x65cf;&#x4eba;&#x7fa4;&#x9057;&#x4f20;&#x6027;&#x5468;&#x56f4;&#x795e;&#x7ecf;&#x75c5;(hereditary peripheral neuropathy&#xff0c;HPN)&#x81f4;&#x75c5;&#x57fa;&#x56e0;&#x7684;&#x5206;&#x5e03;&#x7279;&#x70b9;&#xff0c;&#x63a2;&#x8ba8;HPN&#x4e0e;&#x76f8;&#x5173;&#x75be;&#x75c5;&#x7684;&#x6f5c;&#x5728;&#x53d1;&#x75c5;&#x673a;&#x5236;&#x548c;&#x6cbb;&#x7597;&#x524d;&#x666f;&#x3002;</AbstractText><AbstractText Label="&#x65b9;&#x6cd5;">&#x6536;&#x96c6;2007&#x5e74;1&#x6708;&#x5230;2022&#x5e74;5&#x6708;&#x5728;&#x5317;&#x4eac;&#x5927;&#x5b66;&#x7b2c;&#x4e09;&#x533b;&#x9662;&#x548c;&#x4e2d;&#x65e5;&#x53cb;&#x597d;&#x533b;&#x9662;&#x8bca;&#x6cbb;&#x7684;HPN&#x5148;&#x8bc1;&#x8005;666&#x4e2a;&#xff0c;&#x7528;&#x591a;&#x91cd;&#x8fde;&#x63a5;&#x63a2;&#x9488;&#x6269;&#x589e;&#x6280;&#x672f;&#x786e;&#x5b9a;<i>PMP22</i>&#x91cd;&#x590d;&#x548c;&#x7f3a;&#x5931;&#x7a81;&#x53d8;&#x540e;&#xff0c;&#x7528;&#x4e8c;&#x4ee3;&#x6d4b;&#x5e8f;&#x57fa;&#x56e0;&#x5305;&#x6216;&#x5168;&#x5916;&#x663e;&#x5b50;&#x7ec4;&#x6d4b;&#x5e8f;&#xff0c;Sanger&#x6cd5;&#x8fdb;&#x884c;&#x4e00;&#x4ee3;&#x9a8c;&#x8bc1;&#xff0c;&#x5206;&#x6790;&#x6bd4;&#x8f83;&#x7ed3;&#x679c;&#x3002;</AbstractText><AbstractText Label="&#x7ed3;&#x679c;">&#x8153;&#x9aa8;&#x808c;&#x840e;&#x7f29;&#x75c7;(Charcot-Marie-Tooth&#xff0c;CMT)&#x5728;HPN&#x4e2d;&#x6240;&#x5360;&#x6bd4;&#x4f8b;&#x6700;&#x9ad8;&#xff0c;&#x4e3a;74.3%(495/666)&#xff0c;&#x5176;&#x4e2d;69.1%(342/495)&#x7684;&#x60a3;&#x8005;&#x83b7;&#x5f97;&#x57fa;&#x56e0;&#x786e;&#x8bca;&#x3002;&#x6700;&#x5e38;&#x89c1;&#x7684;&#x57fa;&#x56e0;&#x7a81;&#x53d8;&#x4e3a;<i>PMP22</i>&#x91cd;&#x590d;&#x3001;<i>MFN2</i>&#x548c;<i>GJB1</i>&#x7a81;&#x53d8;&#xff0c;&#x5360;CMT&#x603b;&#x4f53;&#x786e;&#x8bca;&#x60a3;&#x8005;&#x7684;71.3%(244/342)&#x3002;&#x9057;&#x4f20;&#x6027;&#x8fd0;&#x52a8;&#x795e;&#x7ecf;&#x75c5;(hereditary motor neuropathy&#xff0c;HMN)&#x6240;&#x5360;&#x6bd4;&#x4f8b;&#x4e3a;16.1%(107/666)&#xff0c;43%(46/107)&#x4e3a;&#x57fa;&#x56e0;&#x786e;&#x8bca;&#xff0c;&#x6700;&#x5e38;&#x89c1;&#x7684;&#x57fa;&#x56e0;&#x7a81;&#x53d8;&#x4e3a;<i>HSPB1</i>&#x3001;t-RNA&#x5408;&#x6210;&#x9176;&#x76f8;&#x5173;&#x57fa;&#x56e0;(aminoacyl-tRNA synthetases)&#x548c;<i>SORD</i>&#x7a81;&#x53d8;&#xff0c;&#x5360;HMN&#x603b;&#x4f53;&#x786e;&#x8bca;&#x60a3;&#x8005;&#x7684;50%(23/46)&#x3002;HMN&#x7684;&#x90e8;&#x5206;&#x57fa;&#x56e0;&#x53ef;&#x4ee5;&#x5408;&#x5e76;&#x591a;&#x79cd;&#x4e34;&#x5e8a;&#x8868;&#x578b;&#xff0c;&#x5982;<i>HSPB1</i>&#x3001;<i>GARS</i>&#x3001;<i>IGHMBP2</i>&#x53ef;&#x540c;&#x65f6;&#x5f15;&#x8d77;HMN&#x548c;CMT&#xff0c;HMN&#x53e0;&#x52a0;&#x7efc;&#x5408;&#x5f81;&#x7684;&#x60a3;&#x8005;&#x4e0e;&#x808c;&#x840e;&#x7f29;&#x4fa7;&#x7d22;&#x786c;&#x5316;(<i>KIF5A</i>&#x3001;<i>FIG4</i>&#x3001;<i>DCTN1</i>&#x3001;<i>SETX</i>&#x3001;<i>VRK1</i>)&#x3001;&#x9057;&#x4f20;&#x6027;&#x75c9;&#x631b;&#x6027;&#x622a;&#x762b;(<i>KIF5A</i>&#x3001;<i>ZFYVE26</i>&#x3001;<i>BSCL2</i>)&#x548c;&#x810a;&#x808c;&#x840e;&#x7f29;&#x75c7;(<i>MORC2</i>&#x3001;<i>IGHMBP2</i>&#x3001;<i>DNAJB2</i>)&#x6709;&#x5171;&#x540c;&#x7684;&#x81f4;&#x75c5;&#x57fa;&#x56e0;&#x3002;&#x9057;&#x4f20;&#x6027;&#x611f;&#x89c9;&#x81ea;&#x4e3b;&#x795e;&#x7ecf;&#x75c5;(hereditary sensory and autosomal neuropathy&#xff0c;HSAN)&#x5728;HPN&#x4e2d;&#x6240;&#x5360;&#x7684;&#x6bd4;&#x4f8b;&#x8f83;&#x5c0f;&#xff0c;&#x4e3a;2.6%(17/666)&#xff0c;&#x6700;&#x5e38;&#x89c1;&#x7684;&#x81f4;&#x75c5;&#x57fa;&#x56e0;&#x4e3a;<i>SPTLC1</i>&#x7a81;&#x53d8;&#x3002;&#x5f15;&#x8d77;&#x9057;&#x4f20;&#x6027;&#x6dc0;&#x7c89;&#x6837;&#x5468;&#x56f4;&#x795e;&#x7ecf;&#x75c5;&#x7684;&#x57fa;&#x56e0;&#x4e3b;&#x8981;&#x662f;<i>TTR</i>&#xff0c;&#x672c;&#x7814;&#x7a76;&#x4e2d;&#x6700;&#x5e38;&#x89c1;&#x7684;&#x57fa;&#x56e0;&#x7a81;&#x53d8;&#x4f4d;&#x70b9;&#x662f;p.A117S&#x548c;p.V50M&#xff0c;&#x8868;&#x73b0;&#x4e3a;&#x665a;&#x53d1;&#x548c;&#x6bd4;&#x8f83;&#x7a81;&#x51fa;&#x7684;&#x81ea;&#x4e3b;&#x795e;&#x7ecf;&#x53d7;&#x7d2f;&#x3002;</AbstractText><AbstractText Label="&#x7ed3;&#x8bba;">CMT&#x548c;HMN&#x662f;&#x6700;&#x5e38;&#x89c1;&#x7684;HPN&#xff0c;HMN&#x4e0e;CMT2&#x7684;&#x81f4;&#x75c5;&#x57fa;&#x56e0;&#x6709;&#x5f88;&#x591a;&#x4ea4;&#x53c9;&#xff0c;&#x90e8;&#x5206;HMN&#x81f4;&#x75c5;&#x57fa;&#x56e0;&#x4e0e;&#x808c;&#x840e;&#x7f29;&#x4fa7;&#x7d22;&#x786c;&#x5316;&#x3001;&#x9057;&#x4f20;&#x6027;&#x75c9;&#x631b;&#x6027;&#x622a;&#x762b;&#x548c;&#x810a;&#x808c;&#x840e;&#x7f29;&#x75c7;&#x6709;&#x91cd;&#x53e0;&#xff0c;&#x63d0;&#x793a;&#x4e0d;&#x540c;&#x75be;&#x75c5;&#x4e4b;&#x95f4;&#x53ef;&#x80fd;&#x5b58;&#x5728;&#x6f5c;&#x5728;&#x7684;&#x5171;&#x540c;&#x81f4;&#x75c5;&#x901a;&#x8def;&#x3002;</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">China</Keyword><Keyword MajorTopicYN="N">Genes</Keyword><Keyword MajorTopicYN="N">Hereditary sensory and motor neuropathy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>14</Day><Hour>20</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36241230</ArticleId><ArticleId IdType="pmc">PMC9568373</ArticleId><ArticleId IdType="doi">10.19723/j.issn.1671-167X.2022.05.015</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ghosh S, Tourtellotte WG. The complex clinical and genetic landscape of hereditary peripheral neuropathy. Annu Rev Pathol. 2021;16:487&#x2013;509. doi: 10.1146/annurev-pathol-030320-100822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pathol-030320-100822</ArticleId><ArticleId IdType="pubmed">33497257</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansagi B, Griffin H, Whittaker RG, et al. Genetic heterogeneity of motor neuropathies. Neurology. 2017;88(13):1226&#x2013;1234. doi: 10.1212/WNL.0000000000003772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003772</ArticleId><ArticleId IdType="pmc">PMC5373778</ArticleId><ArticleId IdType="pubmed">28251916</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossor AM, Polke JM, Houlden H, et al. Clinical implications of genetic advances in Charcot-Marie-Tooth disease. Nat Rev Neurol. 2013;9(10):562&#x2013;571. doi: 10.1038/nrneurol.2013.179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.179</ArticleId><ArticleId IdType="pubmed">24018473</ArticleId></ArticleIdList></Reference><Reference><Citation>Previtali SC, Zhao E, Lazarevic D, et al. Expanding the spectrum of genes responsible for hereditary motor neuropathies. J Neurol Neurosurg Psychiatry. 2019;90(10):1171&#x2013;1179. doi: 10.1136/jnnp-2019-320717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-320717</ArticleId><ArticleId IdType="pubmed">31167812</ArticleId></ArticleIdList></Reference><Reference><Citation>Beijer D, Baets J. The expanding genetic landscape of hereditary motor neuropathies. Brain. 2020;143(12):3540&#x2013;3563. doi: 10.1093/brain/awaa311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa311</ArticleId><ArticleId IdType="pubmed">33210134</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein CJ. Charcot-Marie-Tooth disease and other hereditary neuropathies. Continuum (Minneap Minn) 2020;26(5):1224&#x2013;1256.</Citation><ArticleIdList><ArticleId IdType="pubmed">33003000</ArticleId></ArticleIdList></Reference><Reference><Citation>Magy L, Mathis S, Le Masson G, et al. Updating the classification of inherited neuropathies: Results of an international survey. Neurology. 2018;90(10):e870&#x2013;e876. doi: 10.1212/WNL.0000000000005074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005074</ArticleId><ArticleId IdType="pubmed">29429969</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaudin M, Klein CJ, Rouleau GA, et al. Systematic review of autosomal recessive ataxias and proposal for a classification. Cerebellum Ataxias. 2017;4:3. doi: 10.1186/s40673-017-0061-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40673-017-0061-y</ArticleId><ArticleId IdType="pmc">PMC5324265</ArticleId><ArticleId IdType="pubmed">28250961</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SM, Herrmann DN, McDermott MP, et al. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst. 2011;16(3):191&#x2013;198. doi: 10.1111/j.1529-8027.2011.00350.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1529-8027.2011.00350.x</ArticleId><ArticleId IdType="pmc">PMC3754828</ArticleId><ArticleId IdType="pubmed">22003934</ArticleId></ArticleIdList></Reference><Reference><Citation>Padilha JPD, Brasil CS, Hoefel AML, et al. Diagnostic yield of targeted sequential and massive panel approaches for inherited neuropathies. Clin Genet. 2020;98(2):185&#x2013;190. doi: 10.1111/cge.13793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cge.13793</ArticleId><ArticleId IdType="pubmed">32506583</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405&#x2013;424. doi: 10.1038/gim.2015.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2015.30</ArticleId><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Lin Z, Liu L, et al. Genotype and phenotype distribution of 435 patients with Charcot-Marie-Tooth from central south China. Eur J Neurol. 2021;28(11):3774&#x2013;3783. doi: 10.1111/ene.15024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15024</ArticleId><ArticleId IdType="pubmed">34255403</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaeth S, Christensen R, Dun&#x3d5; M, et al. Genetic analysis of Charcot-Marie-Tooth disease in Denmark and the implementation of a next generation sequencing platform. Eur J Med Genet. 2019;62(1):1&#x2013;8. doi: 10.1016/j.ejmg.2018.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmg.2018.04.003</ArticleId><ArticleId IdType="pubmed">29653220</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x5218; &#x5c0f;&#x7487;, &#x5b59; &#x963f;&#x840d;, &#x6bb5; &#x6653;&#x6167;, et al. &#x4e2d;&#x56fd;&#x4eba;&#x7fa4;&#x8153;&#x9aa8;&#x808c;&#x840e;&#x7f29;&#x75c7;&#x7684;&#x81f4;&#x75c5;&#x57fa;&#x56e0;&#x5206;&#x5e03;&#x5bf9;&#x6bd4;&#x7814;&#x7a76;&#x2014;&#x2014;14&#x5e74;&#x961f;&#x5217;&#x89c2;&#x5bdf;. &#x4e2d;&#x534e;&#x795e;&#x7ecf;&#x79d1;&#x6742;&#x5fd7;. 2022;55(5):481&#x2013;489. doi: 10.3760/cma.j.cn113694-20211102-00762.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn113694-20211102-00762</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortese A, Zhu Y, Rebelo AP, et al. Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes. Nat Genet. 2020;2(5):473&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8353599</ArticleId><ArticleId IdType="pubmed">32367058</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevilla T, Lupo V, Mart&#xed;nez-Rubio D, et al. Mutations in the MORC2 gene cause axonal Charcot-Marie-Tooth disease. Brain. 2016;139(Pt 1):62&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">26497905</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Duan X, Zhang Y, et al. Molecular analysis and clinical diversity of distal hereditary motor neuropathy. Eur J Neurol. 2020;27(7):1319&#x2013;1326. doi: 10.1111/ene.14260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14260</ArticleId><ArticleId IdType="pubmed">32298515</ArticleId></ArticleIdList></Reference><Reference><Citation>Evgrafov OV, Mersiyanova I, Irobi J, et al. Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. Nat Genet. 2004;36(6):602&#x2013;606. doi: 10.1038/ng1354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1354</ArticleId><ArticleId IdType="pubmed">15122254</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonellis A, Ellsworth RE, Sambuughin N, et al. Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type &#x2164;. Am J Hum Genet. 2003;72(5):1293&#x2013;1299. doi: 10.1086/375039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/375039</ArticleId><ArticleId IdType="pmc">PMC1180282</ArticleId><ArticleId IdType="pubmed">12690580</ArticleId></ArticleIdList></Reference><Reference><Citation>Latour P, Thauvin-Robinet C, Baudelet-Mery C, et al. A major determinant for binding and aminoacylation of tRNA (Ala) in cytoplasmic Alanyl-tRNA synthetase is mutated in dominant axonal Charcot-Marie-Tooth disease. Am J Hum Genet. 2010;86(1):77&#x2013;82. doi: 10.1016/j.ajhg.2009.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2009.12.005</ArticleId><ArticleId IdType="pmc">PMC2801750</ArticleId><ArticleId IdType="pubmed">20045102</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez M, McLaughlin H, Houlden H, et al. Exome sequencing identifies a significant variant in methionyl-tRNA synthetase (MARS) in a family with late-onset CMT2. J Neurol Neurosurg Psychiatry. 2013;84(11):1247&#x2013;1249. doi: 10.1136/jnnp-2013-305049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-305049</ArticleId><ArticleId IdType="pmc">PMC3796032</ArticleId><ArticleId IdType="pubmed">23729695</ArticleId></ArticleIdList></Reference><Reference><Citation>Vester A, Velez-Ruiz G, McLaughlin HM, et al. A loss-of-function variant in the human histidyl-tRNA synthetase (HARS) gene is neurotoxic in vivo. Hum Mutat. 2013;34(1):191&#x2013;199. doi: 10.1002/humu.22210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22210</ArticleId><ArticleId IdType="pmc">PMC3535524</ArticleId><ArticleId IdType="pubmed">22930593</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai PC, Soong BW, Mademan I, et al. A recurrent WARS mutation is a novel cause of autosomal dominant distal hereditary motor neuropathy. Brain. 2017;140(5):1252&#x2013;1266. doi: 10.1093/brain/awx058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx058</ArticleId><ArticleId IdType="pmc">PMC6248622</ArticleId><ArticleId IdType="pubmed">28369220</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan RY, Ye ZL, Zhang XR, et al. Evaluation of SORD mutations as a novel cause of Charcot-Marie-Tooth disease. Ann Clin Transl Neurol. 2021;8(1):266&#x2013;270. doi: 10.1002/acn3.51268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51268</ArticleId><ArticleId IdType="pmc">PMC7818235</ArticleId><ArticleId IdType="pubmed">33314640</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarlino S, Domi T, Pozzi L, et al. Burden of rare variants in ALS and axonal hereditary neuropathy genes influence survival in ALS: Insights from a next generation sequencing study of an Italian ALS cohort. Int J Mol Sci. 2020;21(9):3346. doi: 10.3390/ijms21093346.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21093346</ArticleId><ArticleId IdType="pmc">PMC7246633</ArticleId><ArticleId IdType="pubmed">32397312</ArticleId></ArticleIdList></Reference><Reference><Citation>Montecchiani C, Pedace L, Giudice TL, et al. ALS5/SPG11/KIAA1840 mutations cause autosomal recessive axonal Charcot-Marie-Tooth disease. Brain. 2016;139(Pt 1):73&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839554</ArticleId><ArticleId IdType="pubmed">26556829</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D, Yilmaz R, Muller K, et al. Hot-spot KIF5A mutations cause familial ALS. Brain. 2018;141(3):688&#x2013;697. doi: 10.1093/brain/awx370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx370</ArticleId><ArticleId IdType="pmc">PMC5837483</ArticleId><ArticleId IdType="pubmed">29342275</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Liu X, Tang L, et al. Whole-exome sequencing identified novel KIF5A mutations in Chinese patients with amyotrophic lateral sclerosis and Charcot-Marie-Tooth type 2. J Neurol Neurosurg Psychiatry. 2020;91(3):326&#x2013;328. doi: 10.1136/jnnp-2019-320483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-320483</ArticleId><ArticleId IdType="pubmed">31422367</ArticleId></ArticleIdList></Reference><Reference><Citation>Stavrou M, Sargiannidou I, Georgiou E, et al. Emerging Therapies for Charcot-Marie-Tooth Inherited Neuropathies. Int J Mol Sci. 2021;22(11):6048. doi: 10.3390/ijms22116048.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22116048</ArticleId><ArticleId IdType="pmc">PMC8199910</ArticleId><ArticleId IdType="pubmed">34205075</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejaoui K, Wu C, Scheffler MD, et al. SPTLC1 is mutated in hereditary sensory neuropathy, type 1. Nat Genet. 2001;27(3):261&#x2013;262. doi: 10.1038/85817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/85817</ArticleId><ArticleId IdType="pubmed">11242106</ArticleId></ArticleIdList></Reference><Reference><Citation>Eichler FS, Hornemann T, McCampbell A, et al. Overexpression of the wild-type SPT1 subunit lowers desoxysphingolipid levels and rescues the phenotype of HSAN1. J Neurosci. 2009;29(46):14646&#x2013;14651. doi: 10.1523/JNEUROSCI.2536-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2536-09.2009</ArticleId><ArticleId IdType="pmc">PMC3849752</ArticleId><ArticleId IdType="pubmed">19923297</ArticleId></ArticleIdList></Reference><Reference><Citation>Fridman V, Suriyanarayanan S, Novak P, et al. Randomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1. Neurology. 2019;92(4):e359&#x2013;e370. doi: 10.1212/WNL.0000000000006811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006811</ArticleId><ArticleId IdType="pmc">PMC6345118</ArticleId><ArticleId IdType="pubmed">30626650</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohassel P, Donkervoort S, Lone MA, et al. Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis. Nat Med. 2021;27(7):1197&#x2013;1204. doi: 10.1038/s41591-021-01346-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01346-1</ArticleId><ArticleId IdType="pmc">PMC9309980</ArticleId><ArticleId IdType="pubmed">34059824</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Liu Z, Zhang Y, et al. Corneal sub-basal whorl-like nerve plexus: A landmark for early and follow-up evaluation in transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2021;28(2):630&#x2013;638. doi: 10.1111/ene.14563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14563</ArticleId><ArticleId IdType="pubmed">33098366</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum JN. Oligonucleotide drugs for transthyretin amyloidosis. N Engl J Med. 2018;379(1):82&#x2013;85. doi: 10.1056/NEJMe1805499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMe1805499</ArticleId><ArticleId IdType="pubmed">29972750</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser AC, Klein CJ. Wild-type TTR neuropathy with cardiomyo-pathy presenting with burning feet. Neurology. 2017;88(11):1101&#x2013;1102. doi: 10.1212/WNL.0000000000003721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003721</ArticleId><ArticleId IdType="pubmed">28289168</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>